At Real Endpoints we are always excited to celebrate National Pharmacists Day to recognize the contributions to healthcare delivery our pharmacist colleagues and friends make each and every day. Thank you!
read full article ›A recent opinion piece by Sree Chaguturu, Chief Medical Officer, #cvshealth raises some interesting points about sustainable ways to INCREASE specialty drug coverage through innovative strategies. Two ideas caught our attention - combining coverage for all specialty medications (including those currently under the medical benefit), under the pharmacy benefit; and requiring value-based agreements (VBAs), where costs are aligned with clinical outcomes and effectiveness.
read full article ›Take a look at the year-end edition of Real Viewpoints, a newsletter for senior decision makers. In this edition we discussed rare and orphan disease coverage issues.
read full article ›Not surprisingly, the Abbott Report - Improving Patient Experience by Addressing Unmet Needs in Vascular Disease highlights the disparity between a patient’s actual experience and the physician / healthcare administrator’s perceptions of a patient’s experience.
read full article ›A very clever idea: a value-based agreement between drug company and, as our own Susan Raiola points out, the Medicare patient (though payer wins, too).
read full article ›An interesting piece (featuring our very own Roger Longman and Susan Raiola) on the growing focus on lung cancer drugs for value based deals.
read full article ›This is the specialty pharmacy version of “who moved my cheese.” In news that is surprising to no one, hospital affiliated specialty pharmacies don’t like vertically integrated payers and their affiliated SPs getting in the way of revenues (sorry, patient care), through white bagging. We wonder if those same payers and their SPs see it differently?
read full article ›Although limited in scope (and arguably impact), Express Scripts has joined the trend to reduce patient out-of-pocket expenses at the pharmacy counter. But before taking a victory lap, one big question remains - how do we reduce the financial burden for the other 98%?
read full article ›A wake up call for manufacturers - regardless of your opinion of ICER there is an indisputable truth outlined in this research - that drug coverage and market access are NOT the same thing.
read full article ›With the holidays right around the corner, ICER has published its 2020 naughty list. Not surprising to anyone familiar with the autoimmune category, Humira makes the list for a third year in a row. How much of the net price increase was driven by an expected entry of biosimilar HUM in 2023 and how much can/will be corrected after that market event remains to be seen. But make no mistake, ICER is making their list and checking it twice…
read full article ›